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Introduction: Ototoxicity associated with platinum-based chemotherapy is highly prevalent and can 
cause detrimental consequences among cancer survivors.  
Discussion: In this article, we highlight important aspects of the evaluation of ototoxicity with the aim 
to increase awareness of Oncologists in this regard. Standard pure tone audiometry alone is inadequate 
for this context. Comprehensive and consistent hearing tests should be implemented in a monitoring 
and surveillance program. High-frequency audiometry (10-16 kHz) is a sensitive tool in the detection of 
ototoxic hearing loss at onset. In addition to threshold audiometry, measures of speech comprehension 
(both in quiet and in noise) can add useful information in the evaluation of hearing in real life situations. 
Not only hearing loss, but also tinnitus and imbalance are common in patients who receive platinum-
based chemotherapy, and can cause debilitating effects upon quality of life in this population. Moreover, 
self-report measures associated with cochlear and vestibular handicaps can provide valuable 
information regarding the impact of ototoxicity.  
Conclusions: It is vital to build awareness about the variety and impact of the symptoms of ototoxicity. 
Comprehensive evaluation of hearing status along with self-reported impact of the cochlear and 
vestibular handicap should be implemented in a monitoring and surveillance program for appropriate 
investigation and management. 
 













Platinum-based chemotherapies, such as cisplatin and carboplatin, are highly effective 
chemotherapeutic agents used for the treatment of a variety of life-threatening common cancers 
including testicular, gynaecologic, bladder, head and neck, and non-small cell lung cancer [1]. Despite 
potent efficacy against cancer, ototoxic effects are significantly problematic which limit usage and 
dosage [2]. Cisplatin has been found to be the most ototoxic agent in the platinum-based chemotherapy 
group with associated hearing loss [3], tinnitus [4], and imbalance [5]. Carboplatin and oxaliplatin have 
been demonstrated to be less ototoxic [6], though audio-vestibular issues still arise.  
 
Ototoxicity refers to drug-related damage affecting the inner ear structures, specifically to the cochlea 
and the vestibular labyrinth, and their associated neural structures [3,7]. Ototoxic effects can be 
characterized by cochlear dysfunction (such as hearing loss, tinnitus, or hyperacusis) or vestibular 
dysfunction (such as vertigo, dizziness, or imbalance) or both [7]. However, ototoxicity in the published 
literature usually refers to hearing disorders and both terms are used interchangeably [8].  
 
Although hearing loss is not a fatal condition, it can have significant negative impacts on communication 
and health-related quality of life [9], and has been associated with dementia and cognitive impairment 
[10], poor mental health and psychosocial functioning [11]. Approximately 70% of people with hearing 
loss had limited employment opportunities, failed to fulfill their potential at work, and felt isolated at work 
[12]. In children, hearing is substantially associated with speech and language development [13] thus 
hearing impairment can cause detrimental educational, vocational, and social consequences [14]. 
Additionally, it also has a hidden-cost to society, such as reduced work productivity, if people are not 
offered appropriate interventions [15]. 
 
Early identification of ototoxicity might provide oncologists with an opportunity to adjust the 
chemotherapy regimen, either lowering the dosage or change to alternative drug, in order to reduce or 
prevent further hearing deterioration [16]. The primary aim of cancer treatment has been always to 
increase overall survival; however, quality of life has been increasingly documented as an important 
end point [17]. There is a lack of information on efficacy of ototoxicity monitoring and its cost-benefit 
ratio on treatment alteration [16]. There is limited information on the trade‐off between longevity and 
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quality of life cancer patient is willing to make [18]; therefore, the clinical decisions in oncology clinics 
are made on a case-by-case basis. In a study Enoch et al [19] suggested that hearing and balance 
were ranked in top three of the most valuable senses in a general adult population and participants 
preferred, on average, 6.8 years of perfect health over 10 years without hearing in a time tradeoff 
exercise. This indicates that prolonged life with reduced hearing is of diminished value.  
 
Discussion 
Whilst there are many studies that report ototoxicity associated with platinum-based chemotherapy, the 
literature is characterized by small sample sizes, inadequate baseline measures, and non-standard 
reporting of audiometric measures. The prevalence of platinum-based ototoxicity in adults reported in 
the literature is approximately 50-80% [4,20], and 60-90% in children [21,22]. A high inter-individual 
variability in incidence and severity of hearing loss can potentially be explained by differences in 
pharmacokinetics and pharmacodynamics of certain drugs including individual susceptibility factors 
such as genetics [23], and other co-morbid conditions such as renal diseases [24]. Some emerging 
clinical translational research indicates that pre-chemotherapy patient genotyping could help in 
predicting cisplatin-associated ototoxicity when deciding treatment regimens [25,26]. The severity of 
hearing loss associated with platinum-based chemotherapy within each individual seems to be dose-
dependent and cumulative [27]. 
 
In this review, we argue that the prevalence of hearing loss associated with platinum-based 
chemotherapy can only be robustly determined by the consistent and appropriate use of measures of 
hearing in a strict pre, post, and long-term framework. Further, we contend that the standard audiogram, 
a measure of the threshold of pure tone detection in quiet, is not a sufficient measure of real world 
hearing. The use of extended high-frequency audiogram (HFA) (10-16 kHz) facilitates early detection 
of ototoxic hearing loss at onset. Measures of speech comprehension, both in quiet and in noise, should 
also be utilized. Additionally, we discuss that treating ototoxicity as a synonym for hearing loss excludes 
the prevalent issues of tinnitus, and/or imbalance found in this population. Finally, whilst self-report 
measures of auditory or vestibular handicap are imperfect tools, they should be brought to bear in 
studies of platinum induced ototoxicity to determine the impact of ototoxicity.  
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Monitoring ototoxic hearing loss 
Hearing loss caused by ototoxic medication has a relatively predictable pattern as it initially 
preferentially damages outer hair cells in the basal turn of the cochlea and then progresses to the apical 
turn [28]. Therefore, the classic characteristics of drug-induced hearing loss are bilaterally symmetrical 
sensorineural hearing loss that affects high frequencies, typically above 8 kHz [1], which are key 
components of the discrimination of speech in background noise and music perception. Cochlear 
damage often progresses undetected until a substantial hearing communication problem becomes 
apparent suggesting hearing decline in the speech range frequencies. 
 
Conventional pure tone audiometry (PTA) remains the mainstay for the identification and categorisation 
hearing impairment in many ototoxicity grading systems [29]. A PTA may be all the testing that patients 
undergoing chemotherapy can tolerate, and this may be especially true of the paediatric population [8]. 
In some younger children, otoacoustic emissions may present an opportunity to assess cochlear health 
in an ear and frequency specific manner [8,14,30]. Audiological assessments for ototoxicity may differ 
from standard hearing evaluation in the priority of testing frequencies and sequence of testing [30]. High 
frequency audiometry (HFA) is a more sensitive tool in the early identification of ototoxic changes than 
the standard PTA [31,32]. However, HFA requires specific instrumentation, additional test time, and in 
practice a change in hearing higher than 8 kHz generally does not impact the continuation of treatment 
regimen. Studies have revealed the ability to detect early drug-induced cochlear damage through a 
limited behavioral test frequency range, called the sensitive range of ototoxicity (SRO) [33]. The SRO 
is a pure tone screening procedure in which a one-octave individualized range of frequencies at the 
high-frequency limit of hearing is monitored. The SRO is defined as the highest frequency with a 
threshold ≤100 dB followed by 6 lower consecutive frequencies in 1/6th-octave steps; thus, it is unique 
for each individual’s audiometric configuration. Testing these seven frequencies identifies 
approximately 90% of initial ototoxic hearing shifts [34]. The SRO procedure is both sensitive and time-
efficient technique. Identifying the SRO is relatively quick while maintaining the sensitivity compared 
with PTA and HFA, and can be assessed using an extended high-frequency audiometer [33].  
 
Clinically, ototoxicity is diagnosed by comparing functional status before and after the administration of 
ototoxic drugs; hence, baseline evaluation is essential. This prevents inaccurate diagnosis of iatrogenic 
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ototoxic hearing loss actually caused by previous hearing impairment prior to chemotherapy treatment 
such as presbycusis or noise-induced hearing loss. This is particularly important in adult population as 
those conditions share similar audiometric results to those caused by ototoxic medications. Obtaining 
pre- and post-treatment hearing assessments also support basic and clinical research on drugs or 
interventions that can neutralize ototoxicity while not interfering with the efficacy of the anti-neoplastic 
capabilities of chemotherapy. Pre-existing hearing status in combination with cisplatin cumulative dose 
can be useful in the prediction of the degree of ototoxic hearing loss [35]. A tool to help relatively precise 
predictions regarding the potential reduction in hearing in advance of chemotherapy treatment would 
be valuable for pretreatment counselling and oncology treatment planning.   
 
Drug-induced hearing loss is generally irreversible and occurs in a dose-related and cumulative fashion 
[36,35]. Consequently, a regular monitoring program is crucial for the early detection of ototoxicity which 
provides useful information for early detection to minimize irreversible hearing loss as well as timely 
interventions. Hearing impairment after administration of platinum-based compounds can also be 
progressive for years after discontinuation of medication [14], which means hearing loss may not only 
evident in patients who sustained ototoxicity during treatment. In addition, recent evidence shows that 
platinum is retained indefinitely in patients treated with cisplatin [37]. Thus, long-term surveillance is 
necessary because of the potential for progressive or delayed-onset hearing loss. American Speech-
Language-Hearing Association (ASHA) recommends evaluations to be done in 1 and 3 months 
following discontinuation of ototoxic therapy [38]. Recent evidence based guidance on ototoxicity 
monitoring in adolescents and young adults proposed ongoing 5 yearly audiometry [8]. 
 
The use of different criteria and grading systems for ototoxicity has made the analysis of published data 
challenging to interpret and has partly contributed to the variability in reporting the prevalence of drug-
induced hearing loss throughout the literature [39]. Hence, uniformity of classification systems is 
essential to compare the results in both clinical practice and trial settings. A recent review article 
summarized numerous classification systems developed and used to classify cochleotoxicity using 
different audiometric criteria [29]. For example, the Common Terminology Criteria for Adverse Events 
(CTCAE) is widely accepted among the oncology research community as the standard grading scale 
for adverse events in clinical trials. Audiometric results are graded (1–4) according to the threshold 
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change, number of frequencies affected, and indication for intervention. However, the CTCAE version 
4 (2010) and 5 (2017) do not fully encapsulate the functional difference in difficulties experienced 
between a change in threshold from different baselines [29]. 
 
All of the available information emphasizes the importance of coherent and proper hearing 
measurement before, during, and after chemotherapy to determine the incidence and prevalence of 
hearing impairment associated with platinum-based chemotherapy. However, such monitoring 
programs are not routinely implemented [40] despite the existence of clinical guidelines [38,16] and 
recommendations for ototoxicity surveillance [8].   
 
Threshold measures of hearing are insufficient, discrimination measures are needed 
A complaint expressed by people with hearing impairment is of hearing difficulties in noisy environments 
[41], though sometimes hearing loss is not detected with routine hearing testing [42]. PTA, measuring 
tone detection threshold of varying frequency in quiet condition, is a poor indicator of speech recognition 
in noise ability so it may not reflect dynamic real-world hearing status nor predict the handicap produced 
by hearing loss [43]. 
  
Speech discrimination abilities may be affected as well as detection of hearing thresholds after receiving 
platinum-based chemotherapy [44]. Hearing in noise testing is not commonly utilised in ototoxicity 
monitoring programs [38,16] so challenges in hearing discrimination and intelligibility of speech are not 
routinely assessed. We propose that the evaluation of hearing perception in presence of noise in 
addition to the hearing in quiet conditions will add valuable information in comprehensive hearing 
evaluation and help with hearing rehabilitation plan, and therefore should be implemented in clinical 
practice. Examples of clinically-feasible speech-in-noise tests that are quick administer are the Words-
In-Noise (WIN) test and Quick Speech-In-Noise Test (QuickSIN) [45]. 
 
Tinnitus  
Tinnitus is a subjective perception of sound, for example, hissing, whistling or buzzing, without an 
external source [46], and which can lead to significant negative impacts on psychological status and 
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quality of life [47]. Tinnitus is more prevalent in patients with hearing loss compared to normal hearing 
populations [48,49]. Regarding ototoxicity, in a series of adult patients treated with cisplatin, 59% 
experienced tinnitus whereas 18% had hearing loss only and 23% both symptoms [50]. Frisina et al [4] 
reported approximately 40% of testicular cancer survivors who received cisplatin reported tinnitus which 
was significantly correlated with reduced hearing. On the other hand, Arora et al [51] revealed six out 
of fifty-seven (10.5%) patients had tinnitus irrespective of the dose of cisplatin and none of them had 
complained of subjective hearing loss. A recent study evaluated long-term ototoxicity in pediatric 
patients received platinum-based chemotherapy and/or radiotherapy reported that 66.7% of patients 
reported tinnitus although they may have normal hearing detected by standard audiometry [52]. The 
prevalence of tinnitus associated with platinum-induced ototoxicity is unclear in the literature because 
of the scant research in this area but it is likely to be under-reported and under-appreciated [21].  
 
Vestibular symptoms 
Vestibular effects associated with platinum-based chemotherapy are less frequently described in the 
literature compared to auditory symptoms, but can be debilitating [5]. Vestibular dysfunction can trigger 
a deterioration of quality of life including physical impairment that interfere with driving, riding a bicycle, 
and other activities involving good balance, as well as psychological symptoms [53]. More than 50% of 
subjects with dizziness report reduced efficiency at work, 27% changed their jobs, 21% gave up work, 
and patients report other considerable impacts on personal and social life [54]. 
 
Ototoxic medications are generally administered systemically and therefore affect both ears 
simultaneously. Bilateral symmetrical gradual vestibular loss usually results in insidious disequilibrium, 
postural imbalance or oscillopsia [55]. A compensated vestibular loss may not be recognized until the 
patient loses other cues from vision and somatosensory inputs such as when walking in the dark or 
when concomitant peripheral neuropathy is developed [5]. Moreover, there are multiple factors such as 
the general deconditioning of cancer patients that can make the clinical identification of vestibulotoxicity 
more complicated. Most patients are unlikely to have intense symptoms of imbalance; hence, subtle or 
suspicious symptoms of vestibular impairment should be recorded and/or undergo further 
investigations, for example, vertigo, dizziness, double vision, ataxia, and light-headedness [55,56]. 
Vestibulotoxicity associated with platinum-based chemotherapy seems to be under-investigated and 
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underestimated [5]. Clinicians should be vigilant to the presenting symptoms of vestibular impairment 
in this patient population. 
 
Measurement of impact 
Although testing can detect hearing loss at an early stage, the impact upon daily activities and quality 
of life as assessed by self-report is also important. One common limitation of the available 
cochleotoxicity grading systems is a lack of indication of significant clinical change of hearing linked to 
reduced communication function and quality of life [29]. Similar audiological characteristics in different 
individuals may demonstrate varying degrees of communication difficulties [57]. Self-reports of hearing 
difficulty generally have a higher prevalence than test measures in population studies [43], and patients 
may have a substantially greater hearing handicap and disability than would be expected from the 
results of the audiogram [44].  
 
Self-report measures of communication difficulty should complement audiometric examinations in 
monitoring protocol to guide treatment plans and hearing rehabilitation as well as to gain a better 
understanding of the incidence and burden of ototoxicity. An example of patient-reported tools is the 
Scale of Chemotherapy-Induced Neurotoxicity (SCIN) [58]. Patients answer in four categories ‘not at 
all’, ‘a little’, ‘quite a bit’ and ‘very much’ to the questions: ‘Have you suffered from reduced hearing?’ 
and ‘Have you suffered from ringing in your ears?’. The impact of tinnitus and dizziness on quality of 
life can be evaluated using the Tinnitus Handicap Inventory (THI) [59], and the Dizziness Handicap 
Inventory (DHI) [60]. respectively. The use of questionnaires in the paediatric population is not presently 
supported by validated instruments. 
 
Conclusions 
Ototoxicity associated with platinum-based chemotherapy is a salient issue. It should be a priority to 
build awareness among patients and healthcare providers about the significance and variety of 
symptoms of ototoxicity such as reduced hearing, tinnitus, and imbalance. Comprehensive and robust 
baseline hearing tests within a monitoring and surveillance program should be scheduled to assess 
prevalence of hearing loss associated with platinum-based chemotherapy. Measures of speech in noise 
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complement speech discrimination testing in quiet conditions and can add helpful information in the 
evaluation of real life hearing abilities. Furthermore, the potential impact of cochlear and vestibular 
handicap caused by ototoxicity should be assessed by self-report measures. 
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